Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Inflammation Research
Published in: Inflammation Research 1/2011

01-01-2011 | Review

Inflammation as death or life signal in diabetic fracture healing

Author: Tamás Rőszer

Published in: Inflammation Research | Issue 1/2011

Login to get access

Abstract

Increased apoptosis of chondrocytes and osteoblasts and prolonged survival of osteoclasts lead to early destruction of callus tissue and impair bone remodeling in fracture healing of diabetic patients. Diabetes is accompanied by an increased inflammatory state, reactive oxgen species (ROS) generation and accumulation of advanced glycation end products (AGEs), a heterogenous group of toxic metabolites that can induce inflammation. Prolonged hyperglycemia and insulin resistance correlate with increased apoptosis rate and, accordingly, the proapoptotic role of several inflammatory mediators, ROS and AGEs has been also documented. In this review we summarize the most recent reports supporting the idea that inflammatory signaling increases chondrocyte and osteoblast death and prolongs osteoclast survival, resulting in impaired bone regeneration in diabetes. Antagonising inflammatory signal pathways and solution of inflammation may deserve greater attention in the management of diabetic fracture healing.
Literature
1.
Retzepi M, Donos N. The effect of diabetes mellitus on osseous healing. Clin Oral Implants Res. 2010;21(7):673–81.CrossRefPubMed
2.
Botushanov NP, Orbetzova MM. Bone mineral density and fracture risk in patients with type 1 and type 2 diabetes mellitus. Folia Med (Plovdiv). 2009;51:12–7.
3.
4.
Yaturu S, Humphrey S, Landry C, Jain SK. Decreased bone mineral density in men with metabolic syndrome alone and with type 2 diabetes. Med Sci Monit. 2009;15:CR5–9.PubMed
5.
Loder RT. The influence of diabetes mellitus on the healing of closed fractures. Clin Orthop Relat Res. 1988;232:210–6.PubMed
6.
Folk JW, Starr AJ, Early JS. Early wound complications of operative treatment of calcaneus fractures: analysis of 190 fractures. J Orthop Trauma. 1999;13:369–72.CrossRefPubMed
7.
Ketenjian AY, Jafri AM, Arsenis C. Studies on the mechanism of callus cartilage differentiation and calcification during fracture healing. Orthop Clin North Am. 1978;9:43–65.PubMed
8.
Kayal RA, Siqueira M, Alblowi J, McLean J, Krothapalli N, Faibish D, et al. TNF-alpha mediates diabetes enhanced chondrocyte apoptosis during fracture healing and stimulates chondrocyte apoptosis through FOXO-1. J Bone Miner Res. 2010;25:1604–15.
9.
Kayal RA, Alblowi J, McKenzie E, Krothapalli N, Silkman L, Gerstenfeld L, et al. Diabetes causes the accelerated loss of cartilage during fracture repair which is reversed by insulin treatment. Bone. 2009;44:357–63.CrossRefPubMed
10.
Stolzing A, Sellers D, Llewelyn O, Scutt A. Diabetes induced changes in rat mesenchymal stem cells. Cells Tissues Organs. 2010;191:453–65.CrossRefPubMed
11.
Hamada Y, Fujii H, Fukagawa M. Role of oxidative stress in diabetic bone disorder. Bone. 2009;45(Suppl 1):S35–8.CrossRefPubMed
12.
Sheweita SA, Khoshhal KI. Calcium metabolism and oxidative stress in bone fractures: role of antioxidants. Curr Drug Metab. 2007;8:519–25.CrossRefPubMed
13.
Yamagishi S, Nakamura K, Inoue H. Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients. Med Hypotheses. 2005;65:1013–5.CrossRefPubMed
14.
Motyl K, McCabe LR. Streptozotocin, type I diabetes severity and bone. Biol Proced Online. 2009. [Epub ahead of print].
15.
Juhan-Vague I, Morange PE, Alessi MC. The insulin resistance syndrome: implications for thrombosis and cardiovascular disease. Pathophysiol Haemost Thromb. 2002;32:269–73.CrossRefPubMed
16.
Tzanavari T, Giannogonas P, Karalis KP. TNF-alpha and obesity. Curr Dir Autoimmun. 2010;11:145–56.CrossRefPubMed
17.
Kaneto H, Katakami N, Matsuhisa M, Matsuoka TA. Role of reactive oxygen species in the progression of type 2 diabetes and atherosclerosis. Mediat Inflamm. 2010;2010:453892.
18.
Wu W, Wang M, Sun Z, Wang X, Miao J, Zheng Z. The predictive value of TNF-alpha and IL-6 and the incidence of macrovascular complications in patients with type 2 diabetes. Acta Diabetol. 2010. [Epub ahead of print].
19.
Mandrup-Poulsen T, Pickersgill L, Donath MY. Blockade of interleukin 1 in type 1 diabetes mellitus. Nat Rev Endocrinol. 2010;6:158–66.CrossRefPubMed
20.
Todd JA. Etiology of type 1 diabetes. Immunity.2010;32:457–67.
21.
Takino JI, Kobayashi Y, Takeuchi M. The formation of intracellular glyceraldehyde-derived advanced glycation end-products and cytotoxicity. J Gastroenterol. 2010;45:646–55.
22.
Hasnan J, Yusof MI, Damitri TD, Faridah AR, Adenan AS, Norbaini TH. Relationship between apoptotic markers (Bax and Bcl-2) and biochemical markers in type 2 diabetes mellitus. Singapore Med J; 51:50–5.
23.
Civera M, Urios A, Garcia-Torres ML, Ortega J, Martinez-Valls J, Cassinello N, et al. Relationship between insulin resistance, inflammation and liver cell apoptosis in patients with severe obesity. Diabetes Metab Res Rev. 2010;26:187–92.CrossRefPubMed
24.
Desta T, Li J, Chino T, Graves DT. Altered fibroblast proliferation and apoptosis in diabetic gingival wounds. J Dent Res. 2010;89:609–14.CrossRefPubMed
25.
Burgering BM, Medema RH. Decisions on life and death: FOXO Forkhead transcription factors are in command when PKB/Akt is off duty. J Leukoc Biol. 2003;73:689–701.CrossRefPubMed
26.
Rached MT, Kode A, Silva BC, Jung DY, Gray S, Ong H, et al. FoxO1 expression in osteoblasts regulates glucose homeostasis through regulation of osteocalcin in mice. J Clin Invest. (2010) 120:357–68.
27.
Blanco FJ, Ochs RL, Schwarz H, Lotz M. Chondrocyte apoptosis induced by nitric oxide. Am J Pathol. 1995;146:75–85.PubMed
28.
Goldring MB, Berenbaum F. The regulation of chondrocyte function by proinflammatory mediators: prostaglandins and nitric oxide. Clin Orthop Relat Res. 2004;427:S37–46.CrossRefPubMed
29.
Peng H, Zhou JL, Liu SQ, Hu QJ, Ming JH, Qiu B. Hyaluronic acid inhibits nitric oxide-induced apoptosis and dedifferentiation of articular chondrocytes in vitro. Inflamm Res; 59:519–30.
30.
Wu S, Fadoju D, Rezvani G, De Luca F. Stimulatory effects of insulin-like growth factor-I on growth plate chondrogenesis are mediated by nuclear factor-kappaB p65. J Biol Chem. 2008;283:34037–44.CrossRefPubMed
31.
Nilsson A, Ohlsson C, Isaksson OG, Lindahl A, Isgaard J. Hormonal regulation of longitudinal bone growth. Eur J Clin Nutr. 1994;48(Suppl 1):S150–8. discussion S158–60.PubMed
32.
Iwata K, Asawa Y, Fujihara Y, Tanaka Y, Nishizawa S, Nakagawa T, et al. The effects of rapid- or intermediate-acting insulin on the proliferation and differentiation of cultured chondrocytes. Curr Aging Sci. 2010;3:26–33.
33.
Rashid G, Luzon AA, Korzets Z, Klein O, Zeltzer E, Bernheim J. The effect of advanced glycation end-products and aminoguanidine on TNFalpha production by rat peritoneal macrophages. Perit Dial Int. 2001;21:122–9.PubMed
34.
Csaki C, Mobasheri A, Shakibaei M. Synergistic chondroprotective effects of curcumin and resveratrol in human articular chondrocytes: inhibition of IL-1beta-induced NF-kappaB-mediated inflammation and apoptosis. Arthritis Res Ther. 2009;11:R165.CrossRefPubMed
35.
Gangoiti MV, Cortizo AM, Arnol V, Felice JI, McCarthy AD. Opposing effects of bisphosphonates and advanced glycation end-products on osteoblastic cells. Eur J Pharmacol. 2008;600:140–7.CrossRefPubMed
36.
Puddu A, Storace D, Odetti P, Viviani GL. Advanced glycation end-products affect transcription factors regulating insulin gene expression. Biochem Biophys Res Commun. 2010;395:122–5.
37.
Torreggiani M, Liu H, Wu J, Zheng F, Cai W, Striker G, et al. Advanced glycation end product receptor-1 transgenic mice are resistant to inflammation, oxidative stress, and post-injury intimal hyperplasia. Am J Pathol. 2009;175:1722–32.CrossRefPubMed
38.
Aggarwal BB. Targeting Inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals. Annu Rev Nutr. 2010;30:173–99.
39.
Hofso D, Ueland T, Hager H, Jenssen T, Bollerslev J, Godang K, et al. Inflammatory mediators in morbidly obese subjects: associations with glucose abnormalities and changes after oral glucose. Eur J Endocrinol. 2009;161:451–8.CrossRefPubMed
40.
Boyce BF, Yao Z, Xing L. Functions of nuclear factor kappaB in bone. Ann N Y Acad Sci. 2010;1192:367–75.CrossRefPubMed
41.
Kim SJ, Im DS, Kim SH, Ryu JH, Hwang SG, Seong JK, et al. Beta-catenin regulates expression of cyclooxygenase-2 in articular chondrocytes. Biochem Biophys Res Commun. 2002;296:221–6.CrossRefPubMed
42.
Wehling N, Palmer GD, Pilapil C, Liu F, Wells JW, Muller PE, et al. Interleukin-1beta and tumor necrosis factor alpha inhibit chondrogenesis by human mesenchymal stem cells through NF-kappaB-dependent pathways. Arthritis Rheum. 2009;60:801–12.CrossRefPubMed
43.
Cullen SJ, Ponnappan S, Ponnappan U. Proteasome inhibition up-regulates inflammatory gene transcription induced by an atypical pathway of NF-kappaB activation. Biochem Pharmacol. 2010;79:706–14.CrossRefPubMed
44.
Shembade N, Ma A, Harhaj EW. Inhibition of NF-kappaB signaling by A20 through disruption of ubiquitin enzyme complexes. Science; 327:1135–9.
45.
Wu S, De Luca F. Inhibition of the proteasomal function in chondrocytes down-regulates growth plate chondrogenesis and longitudinal bone growth. Endocrinology. 2006;147:3761–8.CrossRefPubMed
46.
Chang TL, Chang CJ, Lee WY, Lin MN, Huang YW, Fan K. The roles of ubiquitin and 26S proteasome in human obesity. Metabolism. 2009;58:1643–8.CrossRefPubMed
47.
Sakamoto K, Sato Y, Shinka T, Sei M, Nomura I, Umeno M, et al. Proteasome subunits mRNA expressions correlate with male BMI: implications for a role in obesity. Obesity (Silver Spring). 2009;17:1044–9.CrossRef
48.
Rolo AP, Palmeira CM. Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. Toxicol Appl Pharmacol. 2006;212:167–78.CrossRefPubMed
49.
Soldatos G, Cooper ME, Jandeleit-Dahm KA. Advanced-glycation end products in insulin-resistant states. Curr Hypertens Rep. 2005;7:96–102.CrossRefPubMed
50.
Webster L, Abordo EA, Thornalley PJ, Limb GA. Induction of TNF alpha and IL-1 beta mRNA in monocytes by methylglyoxal- and advanced glycated endproduct-modified human serum albumin. Biochem Soc Trans. 1997;25:250S.PubMed
51.
Alikhani M, Alikhani Z, Boyd C, MacLellan CM, Raptis M, Liu R, et al. Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways. Bone. 2007;40:345–53.CrossRefPubMed
52.
Santana RB, Xu L, Chase HB, Amar S, Graves DT, Trackman PC. A role for advanced glycation end products in diminished bone healing in type 1 diabetes. Diabetes. 2003;52:1502–10.CrossRefPubMed
53.
Chan WH, Wu HJ, Shiao NH. Apoptotic signaling in methylglyoxal-treated human osteoblasts involves oxidative stress, c-Jun N-terminal kinase, caspase-3, and p21-activated kinase 2. J Cell Biochem. 2007;100:1056–69.CrossRefPubMed
54.
Ambrogini E, Almeida M, Martin-Millan M, Paik JH, Depinho RA, Han L, et al. FoxO-mediated defense against oxidative stress in osteoblasts is indispensable for skeletal homeostasis in mice. Cell Metab. 2010;11:136–46.CrossRefPubMed
55.
Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Kurioka S, Yano S, et al. Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2009;94:45–9.CrossRefPubMed
56.
Kanazawa I, Yamaguchi T, Yamauchi M, Yamamoto M, Kurioka S, Yano S, et al. Serum undercarboxylated osteocalcin was inversely associated with plasma glucose level and fat mass in type 2 diabetes mellitus. Osteoporos Int. 2010. [Epub ahead of print].
57.
van’t Hof RJ, Ralston SH. Nitric oxide and bone. Immunology 2001; 103:255–61.
58.
Grassi F, Fan X, Rahnert J, Weitzmann MN, Pacifici R, Nanes MS, et al. Bone re/modeling is more dynamic in the endothelial nitric oxide synthase(−/−) mouse. Endocrinology. 2006;147:4392–9.CrossRefPubMed
59.
Baldik Y, Diwan AD, Appleyard RC, Fang ZM, Wang Y, Murrell GA. Deletion of iNOS gene impairs mouse fracture healing. Bone. 2005;37:32–6.CrossRefPubMed
60.
Collin-Osdoby P, Nickols GA, Osdoby P. Bone cell function, regulation, and communication: a role for nitric oxide. J Cell Biochem. 1995;57:399–408.CrossRefPubMed
61.
Charbonneau A, Marette A. Inducible nitric oxide synthase induction underlies lipid-induced hepatic insulin resistance in mice: potential role of tyrosine nitration of insulin signaling proteins. Diabetes. 2010;59:861–71.CrossRefPubMed
62.
Nishio K, Shigemitsu M, Kodama Y, Itoh S, Konno N, Satoh R, et al. The effect of pioglitazone on nitric oxide synthase in patients with type 2 diabetes mellitus. J Cardiometab Syndr. 2008;3:200–4.CrossRefPubMed
63.
Son MJ, Lee SB, Byun YJ, Lee HO, Kim HS, Kwon OJ, et al. Sodium nitroprusside induces autophagic cell death in glutathione-depleted osteoblasts. J Biochem Mol Toxicol. 2010. [Epub ahead of print].
64.
65.
Rapuano BE, Bockman RS. Tumor necrosis factor-alpha stimulates phosphatidylinositol breakdown by phospholipase C to coordinately increase the levels of diacylglycerol, free arachidonic acid and prostaglandins in an osteoblast (MC3T3–E1) cell line. Biochim Biophys Acta. 1991;1091:374–84.CrossRefPubMed
66.
Shin SW, Seo CY, Han H, Han JY, Jeong JS, Kwak JY, et al. 15d-PGJ2 induces apoptosis by reactive oxygen species-mediated inactivation of Akt in leukemia and colorectal cancer cells and shows in vivo antitumor activity. Clin Cancer Res. 2009;15:5414–25.CrossRefPubMed
67.
Lee SJ, Kim MS, Park JY, Woo JS, Kim YK. 15-Deoxy-delta 12, 14-prostaglandin J2 induces apoptosis via JNK-mediated mitochondrial pathway in osteoblastic cells. Toxicology. 2008;248:121–9.CrossRefPubMed
68.
Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol. 2010;72:219–46.CrossRefPubMed
69.
Heikkinen S, Auwerx J, Argmann CA. PPARgamma in human and mouse physiology. Biochim Biophys Acta. 2007;1771:999–1013.PubMed
70.
Bell-Parikh LC, Ide T, Lawson JA, McNamara P, Reilly M, FitzGerald GA. Biosynthesis of 15-deoxy-delta12, 14-PGJ2 and the ligation of PPARgamma. J Clin Invest. 2003;112:945–55.PubMed
71.
Jung JY, Yoo CI, Kim HT, Kwon CH, Park JY, Kim YK. Role of mitogen-activated protein kinase (MAPK) in troglitazone-induced osteoblastic cell death. Toxicology. 2007;234:73–82.CrossRefPubMed
72.
Kim SH, Yoo CI, Kim HT, Park JY, Kwon CH, Kim YK. Activation of peroxisome proliferator-activated receptor-gamma (PPARgamma) induces cell death through MAPK-dependent mechanism in osteoblastic cells. Toxicol Appl Pharmacol. 2006;215:198–207.CrossRefPubMed
73.
Lin TH, Yang RS, Tang CH, Lin CP, Fu WM. PPARgamma inhibits osteogenesis via the down-regulation of the expression of COX-2 and iNOS in rats. Bone. 2007;41:562–74.CrossRefPubMed
74.
Szymczyk KH, Freeman TA, Adams CS, Srinivas V, Steinbeck MJ. Active caspase-3 is required for osteoclast differentiation. J Cell Physiol. 2006;209:836–44.CrossRefPubMed
75.
Cloos C, Wahl P, Hasslacher C, Traber L, Kistner M, Jurkuhn K, et al. Urinary glycosylated, free and total pyridinoline and free and total deoxypyridinoline in diabetes mellitus. Clin Endocrinol (Oxf). 1998;48:317–23.CrossRef
76.
Kemink SA, Hermus AR, Swinkels LM, Lutterman JA, Smals AG. Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology. J Endocrinol Invest. 2000;23:295–303.PubMed
77.
Liu R, Bal HS, Desta T, Krothapalli N, Alyassi M, Luan Q, et al. Diabetes enhances periodontal bone loss through enhanced resorption and diminished bone formation. J Dent Res. 2006;85:510–4.CrossRefPubMed
78.
Luegmayr E, Glantschnig H, Wesolowski GA, Gentile MA, Fisher JE, Rodan GA, et al. Osteoclast formation, survival and morphology are highly dependent on exogenous cholesterol/lipoproteins. Cell Death Differ. 2004;11(Suppl 1):S108–18.CrossRefPubMed
79.
Hie M, Yamazaki M, Tsukamoto I. Curcumin suppresses increased bone resorption by inhibiting osteoclastogenesis in rats with streptozotocin-induced diabetes. Eur J Pharmacol. 2009;621:1–9.CrossRefPubMed
80.
Kawashima Y, Fritton JC, Yakar S, Epstein S, Schaffler MB, Jepsen KJ, et al. Type 2 diabetic mice demonstrate slender long bones with increased fragility secondary to increased osteoclastogenesis. Bone. 2009;44:648–55.CrossRefPubMed
81.
Cornish J, MacGibbon A, Lin JM, Watson M, Callon KE, Tong PC, et al. Modulation of osteoclastogenesis by fatty acids. Endocrinology. 2008;149:5688–95.CrossRefPubMed
82.
Wakeyama H, Akiyama T, Kadono Y, Nakamura M, Oshima Y, Nakamura K, et al. Posttranslational regulation of Bim by caspase-3. Ann N Y Acad Sci. 2007;1116:271–80.CrossRefPubMed
83.
Wakeyama H, Akiyama T, Takahashi K, Amano H, Kadono Y, Nakamura M, et al. Negative feedback loop in the Bim-caspase-3 axis regulating apoptosis and activity of osteoclasts. J Bone Miner Res. 2007;22:1631–9.CrossRefPubMed
84.
Oh SR, Sul OJ, Kim YY, Kim HJ, Yu R, Suh JH, et al. Saturated fatty acids enhance osteoclast survival. J Lipid Res. 2010;51:892–9.CrossRefPubMed
85.
Ruan M, Pederson L, Bradley EW, Bamberger AM, Oursler MJ. Transforming growth factor-{beta} coordinately induces suppressor of cytokine signaling 3 and leukemia inhibitory factor to suppress osteoclast apoptosis. Endocrinology. 2010;151:1713–22.
86.
Perez-Sayans M, Somoza-Martin JM, Barros-Angueira F, Rey JM, Garcia-Garcia A. RANK/RANKL/OPG role in distraction osteogenesis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109:679–86.
87.
Grauslund J, Rasmussen LM, Green A, Sjolie AK. Does osteoprotegerin relate to micro- and macrovascular complications in long-term type 1 diabetes? Scand J Clin Lab Invest. 2010;70:188–93.
88.
Lappin DF, Eapen B, Robertson D, Young J, Hodge PJ. Markers of bone destruction and formation and periodontitis in type 1 diabetes mellitus. J Clin Periodontol. 2009;36:634–41.CrossRefPubMed
89.
Nabipour I, Kalantarhormozi M, Larijani B, Assadi M, Sanjdideh Z. Osteoprotegerin in relation to type 2 diabetes mellitus and the metabolic syndrome in postmenopausal women. Metabolism. 2010;59:742–7.
90.
Terekeci HM, Senol MG, Top C, Sahan B, Celik S, Sayan O, et al. Plasma osteoprotegerin concentrations in type 2 diabetic patients and its association with neuropathy. Exp Clin Endocrinol Diabetes. 2009;117:119–23.CrossRefPubMed
91.
Jorgensen GM, Vind B, Nybo M, Rasmussen LM, Hojlund K. Acute hyperinsulinemia decreases plasma osteoprotegerin with diminished effect in type 2 diabetes and obesity. Eur J Endocrinol. 2009;161:95–101.CrossRefPubMed
92.
Lee SK, Huang H, Lee SW, Kim KH, Kim KK, Kim HM, et al. Involvement of iNOS-dependent NO production in the stimulation of osteoclast survival by TNF-alpha. Exp Cell Res. 2004;298:359–68.CrossRefPubMed
93.
van’t Hof RJ, Ralston SH. Cytokine-induced nitric oxide inhibits bone resorption by inducing apoptosis of osteoclast progenitors and suppressing osteoclast activity. J Bone Miner Res. 1997;12:1797–804.CrossRefPubMed
94.
Evans KE, Fox SW. Interleukin-10 inhibits osteoclastogenesis by reducing NFATc1 expression and preventing its translocation to the nucleus. BMC Cell Biol. 2007;8:4.CrossRefPubMed
95.
Wan Y, Chong LW, Evans RM. PPAR-gamma regulates osteoclastogenesis in mice. Nat Med. 2007;13:1496–503.CrossRefPubMed
96.
Peraza MA, Burdick AD, Marin HE, Gonzalez FJ, Peters JM. The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR). Toxicol Sci. 2006;90:269–95.CrossRefPubMed
97.
Kaji H, Naito J, Inoue Y, Sowa H, Sugimoto T, Chihara K. Statin suppresses apoptosis in osteoblastic cells: role of transforming growth factor-beta-Smad3 pathway. Horm Metab Res. 2008;40:746–51.CrossRefPubMed
98.
Luisetto G, Camozzi V. Statins, fracture risk, and bone remodeling. J Endocrinol Invest. 2009;32:32–7.PubMed
99.
Hsu MJ, Chang CK, Chen MC, Chen BC, Ma HP, Hong CY, et al. Apoptosis signal-regulating kinase 1 in peptidoglycan-induced COX-2 expression in macrophages. J Leukoc Biol. 2010;87:1069–82.CrossRefPubMed
Metadata
Title
Inflammation as death or life signal in diabetic fracture healing
Author
Tamás Rőszer
Publication date
01-01-2011
Publisher
SP Birkhäuser Verlag Basel
Published in
Inflammation Research / Issue 1/2011
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-010-0246-9

Other articles of this Issue 1/2011

Inflammation Research 1/2011 Go to the issue

History of inflammation

Sir James Black and the European Histamine Research Society

Original Research Paper

The effects of lazaroid U-74389G in a rat sepsis model

Original Research Paper

Intrahepatic levels of PD-1/PD-L correlate with liver inflammation in chronic hepatitis B

Original Research Paper

Thromboxane-prostanoid receptor expression and antagonism in dextran-sodium sulfate-induced colitis

Editorial

Inflammation Research: modern design, more quality science

Original Research Paper

The macrophage pattern recognition scavenger receptors SR-A and CD36 protect against microbial induced pregnancy loss
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits